Endotis Pharma Reports The Successful Completion Of Phase I Clinical Trials Of The Neutralizable Anticoagulant EP217609 And Its Antidote Avidin Under Development For Use In Heart Surgery

Published: Apr 30, 2010

Biocitech Park, Paris (France), April 30, 2010 - Endotis Pharma, the biopharmaceutical company dedicated to the discovery and development of small glyco-drugs, announced that the neutralizable anticoagulant EP217609 and its specific antidote avidin have successfully completed their respective first-in-man Phase I clinical trials.

Back to news